Oncologix Tech Stock Retained Earnings
| OCLG Stock | USD 0.0001 0.00 0.00% |
Oncologix Tech fundamentals help investors to digest information that contributes to Oncologix Tech's financial success or failures. It also enables traders to predict the movement of Oncologix Pink Sheet. The fundamental analysis module provides a way to measure Oncologix Tech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Oncologix Tech pink sheet.
Oncologix |
Oncologix Tech Company Retained Earnings Analysis
Oncologix Tech's Retained Earnings is a balance sheet account that refers to the portion of company income that is retained by the firm. In other words, it is a part of earnings that is not paid out as dividends or otherwise distributed to owners. Retained Earnings are calculated by adding net income to last period retained earnings and subtracting any dividends paid to owners.
More About Retained Earnings | All Equity Analysis
Retained Earnings | = | Beginning RE + Income | - | Dividends |
Current Oncologix Tech Retained Earnings | (49.86 M) |
Most of Oncologix Tech's fundamental indicators, such as Retained Earnings, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Oncologix Tech is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Retained Earnings shows how the firm utilizes its profits over time. In simple terms, investors can think of retained earnings as the amount of profit the company has reinvested in the business since its inceptions. However the methodology to make a decision over how much profit to retain is different between companies in different industries. For example, growing industries tend to retain more of their earnings than more matured industries as they need more assets investment to sustain their growth.
| Competition |
Based on the latest financial disclosure, Oncologix Tech has a Retained Earnings of (49.86 Million). This is 100.33% lower than that of the Health Care Providers & Services sector and significantly lower than that of the Health Care industry. The retained earnings for all United States stocks is 100.53% higher than that of the company.
Did you try this?
Run Theme Ratings Now
Theme RatingsDetermine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance |
| All Next | Launch Module |
Oncologix Fundamentals
| Return On Asset | -0.12 | |||
| Profit Margin | (0.38) % | |||
| Operating Margin | (0.13) % | |||
| Current Valuation | 3.18 M | |||
| Shares Outstanding | 340.13 M | |||
| Price To Earning | (0.03) X | |||
| Price To Sales | 0.17 X | |||
| Revenue | 2.85 M | |||
| Gross Profit | 614.41 K | |||
| EBITDA | (572.25 K) | |||
| Net Income | (2.37 M) | |||
| Cash And Equivalents | 86.31 K | |||
| Total Debt | 3.97 M | |||
| Current Ratio | 0.28 X | |||
| Book Value Per Share | (0) X | |||
| Cash Flow From Operations | (24.2 K) | |||
| Earnings Per Share | (0.01) X | |||
| Number Of Employees | 191 | |||
| Beta | 1.27 | |||
| Market Capitalization | 612.23 K | |||
| Total Asset | 1.5 M | |||
| Retained Earnings | (49.86 M) | |||
| Working Capital | (3.35 M) | |||
| Current Asset | 1.31 M | |||
| Current Liabilities | 4.67 M | |||
| Z Score | -47.6 | |||
| Net Asset | 1.5 M |
About Oncologix Tech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Oncologix Tech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Oncologix Tech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Oncologix Tech based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Oncologix Pink Sheet
Oncologix Tech financial ratios help investors to determine whether Oncologix Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Oncologix with respect to the benefits of owning Oncologix Tech security.